



## BioLineRx to Report Third Quarter 2020 Results on November 23, 2020

November 18, 2020 12:00 PM IST

### **Management to hold a conference call at 10:00 a.m. EST**

TEL AVIV, Israel, Nov. 18, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended September 30, 2020 on Monday, November 23, 2020, before the US markets open.

The Company will host a conference call on Monday, November 23, 2020 at 10:00 a.m. EST featuring remarks by Philip Serlin, Chief Executive Officer. The conference call will be available via webcast and can be accessed through the [Investor Relations](#) page of BioLineRx's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.

To dial into the conference call, please dial +1-866-744-5399 from the U.S. or +972-3-918-0664 internationally. A replay of the conference call will be available approximately two hours after completion of the live conference call on the [Investor Relations](#) page of BioLineRx's website. A dial-in replay of the call will be available until November 25, 2020; please dial +1-877-456-0009 from the U.S. or +972-3-925-5929 internationally.

### **About BioLineRx**

BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a late clinical-stage biopharmaceutical company focused on oncology. The Company's business model is to in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development and/or commercialization.

The Company's lead program, Motixafortide (BL-8040), is a cancer therapy platform currently being evaluated in a Phase 3 study in stem cell mobilization for autologous bone-marrow transplantation. Motixafortide is also being evaluated in a Phase 2a study for the treatment of pancreatic cancer in combination with KEYTRUDA® and chemotherapy under a collaboration agreement with MSD, as well as a Phase 2b study in consolidation AML.

BioLineRx is developing a second oncology program, AGI-134, an immunotherapy treatment for multiple solid tumors that is currently being investigated in a Phase 1/2a study.

For additional information on BioLineRx, please visit the Company's website at [www.biolinerx.com](http://www.biolinerx.com), where you can review the Company's SEC filings, press releases, announcements and events. BioLineRx industry updates are also regularly updated on [Facebook](#), [Twitter](#), and [LinkedIn](#).

### **Contact:**

Tim McCarthy  
LifeSci Advisors, LLC  
+1-212-915-2564  
[tim@lifesciadvisors.com](mailto:tim@lifesciadvisors.com)

or

Moran Meir  
LifeSci Advisors, LLC  
+972-54-476-4945  
[moran@lifesciadvisors.com](mailto:moran@lifesciadvisors.com)

 View original content: <http://www.prnewswire.com/news-releases/biolinerx-to-report-third-quarter-2020-results-on-november-23-2020-301175789.html>

SOURCE BioLineRx Ltd.